Delivery Order SPE2DB25D3404-SPE2DB25FUNGW
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,604.51. This is a firm fixed price delivery order with an ultimate completion date of August 15, 2025, executed under a competitive procurement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,070.57. This non-set-aside, competitively awarded contract reflects the firm fixed-price delivery model that characterizes federal pharmaceutical procurement through the DLA's medical supply chain. The order is scheduled for ultimate completion on June 26, 2025, and will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $3,904.42. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,405.80. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement, reflecting the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,686.96. This firm fixed-price delivery order is scheduled for ultimate completion on April 25, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award utilized no set-aside designation, indicating it was competitively awarded through standard...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $3,132.65. This is a firm fixed-price delivery order with an ultimate completion date of August 1, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 4, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $6,387.57. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of June 5, 2025. This delivery order is issued under...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUNGWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 6, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a contract ceiling value of $2,679.66 and an ultimate completion date of May 7, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The parent contract functions as a comprehensive pharmaceutical prime vendor agreement supporting military healthcare systems globally, enabling the company to deliver brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen has demonstrated consistent capability to fulfill competitive federal healthcare supply requirements, including diabetes medications and specialized healthcare commodities for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.7k | 5/6/25 |